

Beneficial effects of ketogenic diets for cancer patients: a realist review with focus on evidence and confirmation

Rainer J. Klement¹

Received: 22 May 2017 / Accepted: 23 June 2017
© Springer Science+Business Media, LLC 2017

Abstract Ketogenic diets (KDs) have gained popularity among patients and researchers alike due to their putative anti-tumor mechanisms. However, the question remains which conclusions can be drawn from the available human data thus far concerning the safety and efficacy of KDs for cancer patients. A realist review utilizing a matrix analytical approach was conducted according to the RAMESES publication standards. All available human studies were systematically analyzed and supplemented with results from animal studies. Evidence and confirmation were treated as separate concepts. In total, 29 animal and 24 human studies were included in the analysis. The majority of animal studies (72%) yielded evidence for an anti-tumor effect of KDs. Evidential support for such effects in humans was weak and limited to individual cases, but a probabilistic argument shows that the available data strengthen the belief in the anti-tumor effect hypothesis at least for some individuals. Evidence for pro-tumor effects was lacking completely. Feasibility of KDs for cancer patients has been shown in various contexts. The probability of achieving an anti-tumor effect seems greater than that of causing serious side effects when offering KDs to cancer patients. Future controlled trials would provide stronger evidence for or against the anti-tumor effect hypothesis.

Keywords Cancer · Evidence · Ketogenic diet · Realist synthesis · Realist review

Introduction

Ketogenic diets (KDs) are diets that mimic the metabolic state of fasting by inducing a physiological rise in the two main circulating ketone bodies, acetoacetate and beta-hydroxybutyrate (BHB), above the reference range (typically ≥ 0.5 mmol/l for BHB). KDs have recently gained increased interest for the treatment of a variety of diseases, where they are used either as a stand-alone metabolic therapy or as part of a broader therapeutic approach [1]. One of these diseases is cancer, a chronic systemic disease characterized by dysfunctional mitochondria and an increased dependence on substrate fermentation (in particular glucose) as against oxidative phosphorylation. Theoretically, this provides an ideal target for ketogenic metabolic therapies [2–4]. While mechanistic reasoning based on experimental work and preliminary human studies provide some support for KDs in cancer treatment [5–9], it has been criticized that there is no evidence for KDs being beneficial for cancer patients due to the lack of randomized controlled trials (RCTs). For example, Huebner et al. [10] stated: “*Following scientific practice e.g. with herbs, controlled, if possible randomized clinical studies are mandatory as scientific evidence for the efficacy of a diet and the basis of a positive recommendation. Risks may be derived from case reports and even preclinical data.*” However, such a statement appears problematic for at least four reasons. First, it draws a bad analogy between interventions with single agents such as herbs and a complex dietary change. Second, it does not allow for integrating patient values or patient circumstances [11] when

Electronic supplementary material The online version of this article (doi:10.1007/s12032-017-0991-5) contains supplementary material, which is available to authorized users.

✉ Rainer J. Klement
rainer_klement@gmx.de

¹ Department of Radiotherapy and Radiation Oncology, Leopoldina Hospital Schweinfurt, Robert-Koch-Str. 10, 97422 Schweinfurt, Germany

counseling individual patients. Third, it neglects the possibility of high-quality mechanistic reasoning as another potential source of evidence [11]. Fourth, and more generally, this hierarchical view of evidence, the hallmark of the evidence-based medicine paradigm, is problematic due to the conceptual incompatibility of external and internal validity which cannot both be maximized simultaneously [12, 13]. It should be considered that different research methods complement each other because the types of validity they produce are incompatible and complementary [13]. The reader is invited to do her own thought experiment about how a RCT to test the effects of a KD for cancer patients should be conducted. How should the inclusion and exclusion criteria be formulated? More generally, would findings concerning patients who fulfilled the inclusion criteria be translatable to patients who were or would have been excluded from the study? A recent clinical study testing a KD in advanced cancer patients exemplifies this problem. In this study by Tan-Shalaby et al. [14], most patients had to be recruited from locations more than a 3-h drive away: “Majority of the interested patients who lived locally did not qualify, as they were not US veterans, one reason for inclusion.” [14] Could such a long way to the hospital not possibly confound the results, e.g., due to increased cortisol levels associated with the stress of traveling? This example reveals one of several problems of placing RCTs over other types of studies for deriving evidence, relating to internal versus external validity, specific versus overall treatment effects, and context dependence of the intervention [12]. Several studies on the KD in cancer patients have already been published; to simply dismiss all those as “no evidence” makes the life of the investigator easy, but is epistemologically invalid because it confuses the concepts of data and evidence. Studies by themselves do not constitute evidence but deliver data which are context free; it is the data that *can* constitute evidence but only *within a context provided by competing hypothesis* [15]. Therefore, even small studies and case reports can constitute evidence (although with a priori low strength [11]) if they are relevant for discriminating between two competing hypotheses. Neglecting them would violate the principle of total evidence [16].¹

In an alternative approach, one could therefore collect all available data in order to try answering the questions “does a KD work, and if yes, for which cancer patients, under what circumstances, and how?” Such an approach is

naturally pursued within the philosophy of realism [17–19], which states that “*there is a world that exists independently of our perception of it, and that our theories inform us about the existence and nature of this realm*” [20]. A realist review emphasizes inquiry about the relationship of an intervention with the outcome dependent on the mechanisms that connect them and the context in which this relationship occurs [17].

This work therefore aims to present a systematic realist synthesis of the question whether KDs are beneficial for cancer patients. The review will be complemented by a matrix analysis in order to collate the totality of available evidence [13]. The following review questions were formulated to guide the analysis: (1) Given the data, to what degree should we believe that KDs exert anti-tumor effects in cancer patients? (2) What is the evidence for the hypothesis that KDs have beneficial effects for cancer patients both in terms of an anti-tumor effect as well as improving quality of life (QoL)? (3) What are the mechanisms that researchers put forward to explain their findings? We term the first question the *confirmation* question, the second the *evidence* question [15], and the third the *causation* question.

This review was conducted and structured according to the RAMESES reporting standards for realist synthesis [19].

Materials and methods

Realist reviews were originally designed and still are mainly used for investigating complex policy interventions. However, a KD intervention is certainly also too complex to be compared with a pharmaceutical intervention such as a targeted therapy since it requires behavioral changes in eating patterns, induces complex metabolic changes impacting a multitude of cell signaling pathways and can be implemented in a great variety of ways (examples are the Spanish Mediterranean KD [21], Paleolithic KD [22], Medium-chain triglyceride KD [23] or even a vegan version [24]). I, therefore, chose a realist review approach, but adapted toward a more qualitative analysis by collating all individual research findings in a matrix form. This combination of realist synthesis with matrix analysis was proposed by Walach and Loef [13] and is especially useful for the evaluation of lifestyle and alternative and complementary medicine interventions.

It was planned to utilize every study in which cancer patients had been treated with a KD based on an anti-tumor rationale. Additionally, animal studies were planned to be investigated in order to gain insights into mechanistic reasoning; thereby only those studies in which the diet was started on the day of or after tumor implantation were considered since these mimic the

¹ As most philosophers of science, Carnap [16] who formulated this principle made no clear distinction between evidence, data and confirmation [15]. Within our framework (see Materials and Methods section), his principle of total evidence would better be described as the principle to consider all relevant available data when making inferences about hypotheses.

clinical situation in which a KD is introduced after cancer is already manifested. The primary search was conducted in PubMed on May 10, 2017, using the term “ketogenic diet AND cancer.” A secondary search was conducted in Scopus, reference lists, and a personal electronic library (<https://www.mendeley.com>). From the animal studies, the tumor model, concurrent treatment modality, and outcome were recorded. From the studies on humans, I extracted the study type, number of patients treated, tumor location and stage, type of KD (calorie restricted or not), concurrent treatment, as well as outcomes, context, and proposed mechanisms as applying to the three research questions formulated above.

For answering these questions, a distinction must be made between evidence and confirmation as pointed out by Bandyopadhyay et al. [15]. While confirmation measures the degree of belief in a single hypothesis, the evidence is always evaluated against a second hypothesis. Given some background knowledge or context C , the data D are interpreted as *evidence* for a hypothesis H_1 as against hypothesis H_2 if the likelihood ratio $P(D|H_1 \& C)/P(D|H_2 \& C) > 1$; in contrast D *confirm* a hypothesis H if and only if they raise the posterior probability of H compared to its prior probability, $P(H|D) > P(H)$ [15]. In this way, H_1 is better confirmed by the data than H_2 if $P(H_1|D) > P(H_2|D)$. From Bayes theorem, $P(H|D) = P(H)*P(D|H)/P(D)$, this also implies that in case of a high prior probability $P(H)$ for a hypothesis H , we would stick to believing in H even if there are only few observations supporting it, while in case of a low $P(H)$ observational support for H would have to be large in order to convince us to believe in it [25]. A prior probability for H could be derived, e.g., from preclinical studies [13]. To answer the evidence question, which implies contrasting two hypotheses against each other, the anti-tumor effect hypothesis (predicting effects against tumor growth, metabolism or genetics) and the pro-tumor effect hypothesis (predicting tumor growth promotion) were each compared to the hypothesis of a neutral or no effect, respectively. Similarly, the positive QoL effect hypothesis (hypothesizing an improvement in physical, psychological or emotional functioning through a KD) and the negative QoL effect hypothesis (predicting a QoL detriment) were each compared to the hypothesis that a KD does not affect QoL. Given the non-analytical form of these hypotheses, the judgment of the evidence remained qualitative in the sense that I only asked whether—*ceteris paribus*—the individual study data appear more likely under the considered hypothesis as against its competitor hypothesis or not. The Methods and Results and Discussion sections of the individual studies were used to guide this decision under the consideration of the specific context.


Results

The primary search in PubMed resulted in 157 articles of which 13 were original research papers on tumor patients [14, 26–37], 32 on animals [38–69], two studies on both [70, 71], and two were meta-analysis of animal studies [72, 73]. Another seven animal studies [74–80] and nine human studies [81–89] were identified by the secondary search process. Subsequently, 14 animal studies were excluded because either they initiated the KD prior to tumor cell injection [43, 45, 68, 69] or they had no control group [46] or they basically replicated the results of a previously published tumor model system ([39, 40, 75] replicated [38], [76] replicated [44], [59] replicated [77], [61] replicated [53], [80] replicated [58], and [62, 67] replicated [47, 49]). A flowchart of the search process is given in Fig. 1.

Table 1 provides an overview of the selected patient studies with a focus on the efficacy and QoL outcomes; further details are given in Supplementary Table 1. There were 14 case studies and 10 cohort studies in which a total of 214 patients had been treated with a KD. The results concerning evidence for and against anti-tumor effects of the KD are given in Table 2 together with the results of the animal studies. Details of these animal experiments are given in Supplementary Table 2.

In total, 72% (21/29) of the animal studies provided evidence for anti-tumor effects of the KD, either through slower tumor growth or through longer overall survival times in the treated animals. Only one study found evidence for pro-tumor effects. Noteworthy, this study [66] provided evidence for both anti- and pro-tumor effects, depending on the length of the KD feeding period. The two meta-analyses concluded that there is overall evidence for anti-tumor effects of KDs in mice [72, 73]. Concerning the human data, 42% of the studies (10/24) provided evidence for an anti-tumor effect of KDs. The majority of this evidence came from case reports, in which other hypothesis seemed more unlikely as explanations for the observed responses. In seven studies (29%), the evidence was against the KD positively affecting the course of the disease, but only one study revealed evidence for a pro-tumorigenic effect of the KD [28], which is discussed in more detail below.

The results concerning QoL are given in Table 3. Half of the studies (12/24) revealed improvements in QoL, with evidence coming from case and cohort studies with roughly equal contributions. Only one study using an extremely low-protein KD with many artificial foods provided evidence for a detrimental effect [71]. Most frequent improvements concerned the general condition [26, 27, 36, 84, 85, 87, 88] and neurological function/seizure control in patients with brain tumors [14, 28, 34, 89]. Side effects attributed to the

Fig. 1 Flowchart of the study acquisition process

KD were generally mild and reversible [86]. Weight loss occurred in 11 out of 14 studies in which it was quantified and was associated with grade II fatigue in one patient who underwent a calorie-restricted KD [31].

Three main mechanistic rationales for why researchers chose to implement a KD for cancer patients could be identified (see also [90]):

1. Changes in growth factor and ketone body signaling should affect the complex tumor signaling network, and hence metabolism and growth.
2. The metabolic changes associated with the diet result in alterations of metabolic fuels which are ideally suited for the metabolic demands of the host tissues.
3. KDs increase oxidative stress in tumor cells, making them more vulnerable to oxidative therapies such as radio- and chemotherapy.

Influence on tumor cell metabolism and growth

Decreasing glucose flux to the tumor

Many tumor cells possess dysfunctional mitochondria and lack certain enzymes necessary for effective ketone body utilization. To compensate, tumor cells would have to rely on substrate fermentation for energy production (reviewed in [2, 4]). Many studies mentioned the increased utilization

of glucose with subsequent fermentation to lactate by tumors compared to normal tissues, first described by Otto Warburg and co-workers in 1924 [91]. The authors of these studies hypothesized that a KD could be able to limit glucose flux to metabolically inflexible tumors while providing ketone bodies and fat as an alternative fuel for normal tissue [14, 27, 29–31, 33, 70, 84, 85, 87, 89]. In fact, the very first clinical application of a KD to treat cancer patients was undertaken by the Munich physician Wilhelm Brünings in 1941 based on Warburg's observations and the heuristic that diabetes, hypertensive disease, and cancer are all based on an endocrine disturbance of carbohydrate metabolism [81]. Aiming at a drastic reduction in blood glucose levels Brünings developed a “de-glycation method” (“*Entzuckerungsmethode*”) consisting of a diet with less than 50 g carbohydrates and three injections of depot insulin per day. In two reports [81, 82], he described impressive reductions in tumor size and improvements of QoL that would peak at 2–3 weeks and be sustainable for up to 2–3 months. With more experience, the focus of his treatment apparently shifted toward preparing patients for surgery or radium therapy [82]. While the beneficial effects on QoL could be attributed to the anabolic, analgetic, and anti-inflammatory effects of insulin and eventually the high quality of the diet compared to the standard German diet during World War 2, the reductions in tumor growth are harder to understand and could be judged as evidence for an

Table 1 Human studies on KD and cancer

Study	N	Tumor	Evidence for anti-tumor effect	Evidence for pro-tumor effect	Effect details	Evidence for QoL improvement	Evidence for QoL worsening	QoL details
Brünnings [81]	14	Head and neck	Yes	No	Partial to complete remission in all cases	Yes	No	Improvement in general condition with better appetite, sleep and mood
Brünnings [82]	30	Extra-cranial	Yes	No	Tumor shrinkage	Yes	No	Improvement in general condition and clinical symptoms, important as preparation for radium therapy or surgery
Schulte and Schütz [83]	23	Extra-cranial	No	No	No changes in tumor size (x-ray scans)	Unclear	Unclear	Reduction of pain, euphoria even when worsening of general condition, but also less orientation and tiredness
Fearon et al. [26]	5	Stage IV extra-cranial	NA	NA	NA	Yes	No	WHO performance score change +1; weight gain
Nebeling et al. [27]	1	Grade III anaplastic/cerebellar astrocytoma	Yes	No	About 22.8% decrease in FDG-PET activity at 8 weeks; one patient is still alive after 10 years (L. Nebeling, personal communication with U. Kämmerer)	Yes	No	Reversing weight loss experienced prior to KD, improved body control and coordination
Chu-Shore et al. [28]	5	Renal angiomyolipomas/subependymal giant cell tumors	No	Yes	“Rate of progression or development of new tumors was more than expected”	No	No	One impaired cognitive function, but seizure improvement in others
Zuccoli et al. [84]	1	GBM	Unclear	No	Complete remission, but could have been due to chemo-radiation treatment	Yes	No	Karnofsky index 100%, no neurological complications, BMI change from 25.6 to 20.0 kg/m ²
Schmidt et al. [29]	16	Stage IV extra-cranial	No	No	Death in two patients, PD in five patients, SD in five patients after 12 weeks on KD	Yes	No	Improvement in emotional functioning and insomnia in these very advanced patients
Moore [85]	1	GBM	Yes	No	No abnormal hypermetabolic activity to suggest the presence of metabolically active tumor	Unclear	No	Maintained work and exercise
Fine et al. [86]	10	Stage IV extra-cranial	Unclear	No	“SD/PR in only five subjects was not a remarkable finding for a short study considering the variable course of even aggressive cancers, but it is noteworthy that all subjects with SD/PR exhibited high levels of ketosis”	No	No	Some side effects which were reversible
Schroeder et al. [30]	11	Stage II-IV head and neck	Yes	No	Decline of lactate levels and possible switch to aerobic metabolism	NA	NA	NA

Table 1 continued

Study	N	Tumor	Evidence for anti-tumor effect	Evidence for pro-tumor effect	Effect details	Evidence for QoL improvement	Evidence for QoL worsening	QoL details
Champ et al. [31]	6	GBM	Unclear	No	Median PFS 10.3 months; one patient without evidence of recurrence at 12 months from treatment	No	Unclear	Grade I constipation in two patients; fatigue in patient who underwent CR-KD
Rieger et al. [70]	20	GBM	Unclear	No	Median PFS in patients with stable ketosis 6 weeks versus 3 weeks in the others (p = 0.069)	No	No	NA
Branca et al. [32]	1	Grade 3 breast	Yes	No	Down-regulation of HER2 expression, increase in progesterone receptor expression	NA	NA	NA
Schwartz et al. [33]	2	GBM	No	No	PFS 4 and 12 weeks (MRI scans)	No	Unclear	Further impairment of vision, mobility and cognition
Strowd et al. [34]	8	Low and high grade glioma	Unclear	No	"All participants are living and survival rates for those with progressive GBM are comparable to expected survival"	Yes	No	Seizure reduction
Jansen and Walach [35]	13	Curative (6)/palliative (6)/end stage (1) tumors	Yes	No	Significant improvement if on fully KD	NA	NA	NA
Klement and Sweeney [36]	6	Stage I–IV extra-cranial	Unclear	No	Response as expected after radiotherapy; rapid progress after end of KD in stage IV lung cancer patient	Yes	No	Several subjective measures improved, e.g., chronic migraine vanished, euphoric feeling
Schwalb et al. [88]	6	Stage IV extra-cranial	Yes	No	Shrinkage of tumors; contribution of KD rated as important	Yes	No	Improvements in general condition, returning to "normal life"
Tan-Shalaby et al. [14]	17	Stage IV various tumors	Unclear	No	36% of patients stable or improved at 16 weeks; unexpectedly long survival in one melanoma patient	Yes	No	Some improvement in cognitive functioning, but also side effects (dyspnea, constipation, diarrhea, insomnia)
Toth and Clemens [87]	1	Grade 2 myoepithelial soft palate	Yes	No	Reduction in tumor size despite no pre- or concurrent treatment with other therapies	Yes	No	Improvement in physical fitness and well-being
Abdelbary et al. [89]	3	Grade II astrocytoma (2); GBM (1)	Yes	No	Improved surgical outcome in all patients; favorable response to pre-surgery KD in glioblastoma patient (histopathological examination)	Yes	No	Seizure control; improved cognitive function
Artzi et al. [37]	5	Low and high grade glioma	Unclear	No	Partial response in 1 GBM patient after 2 months KD plus BVZ; SD in one patient with gliomatosis cerebri at 31 months on KD monotherapy	NA	NA	NA

Table 1 continued

Study	N	Tumor	Evidence for anti-tumor effect	Evidence for pro-tumor effect	Effect details	Evidence for QoL improvement	Evidence for QoL worsening	QoL details
Zahra et al. [71]	9	Stage III-IV NSCLC (7) and pancreatic (2) cancer	No	Unclear	Study not powered to detect differences in PFS and OS	No	Yes	Poor compliance (33%) and side effects (possibly diet-related grade 4 hyperuricemia)

BVZ Bevacizumab, *GBM* glioblastoma multiforme, *NSCLC* non-small cell lung cancer, *OS* overall survival, *PD* progressive disease, *PFS* progression free survival, *PR* partial remission, *SD* stable disease

effect specific to the KD. However, subsequently Schulte and Schütz were not able to confirm an anti-tumor effect of Brünings’ method [83].

A KD by itself reduced average blood glucose levels in only a subset of the studies that prescribed no concurrent caloric restriction [26, 27, 31, 86]. Two studies in which patients were advised to always eat to satiety failed to achieve significant reductions in blood glucose levels [36, 70], and this was discussed as a possible reason for the failure to halt tumor progression in the study by Rieger et al. [70]. However, more detailed measurements with microdialysis catheters [30] suggest that although the mean plasma concentration remains fairly stable, glucose spikes are greatly reduced under a KD. To also reduce average blood glucose levels, additional calorie restriction was a feasible option in glioblastoma patients [33, 84, 85, 89].

More recent data imply that besides reducing blood glucose levels, a global rise of ketone bodies and free fatty acids is also important for down-regulating glycolysis. Evidence that a KD can reduce tumor glycolysis in some individuals has been gained from studies utilizing FDG-PET scans [14, 27, 86] as well as microdialysis measurements of tumor lactate concentrations [30]. Jansen and Walach [35] described reductions in the pentose phosphate pathway tumor marker TKTL-1 under a strict KD, providing further evidence for the hypothesis that KDs inhibit tumor glycolysis.

Mechanistically, Fine and colleagues proposed that an “inefficient” Randle cycle [92] occurs in cancer cells upon an inhibition of glycolysis through free fatty acids and ketone bodies; the inefficiency refers to the inability of tumor cells to compensate for the reduced glycolytic ATP production because of mitochondrial dysfunction [92–94]. Palmitic acid, stearic acid, and oleic acid were shown to inhibit key glycolytic enzymes in Ehrlich ascites tumor cells [95]. Studies on the anti-tumor effects of oleic acid date back to the 1920s [96, 97]; its intake as part of a KD was therefore emphasized by Ruggiero and colleagues, in part also based on the rationale that oleic acid increases the bioavailability of vitamin D₃ [32, 88].

Schwartz et al. [33] found that ketolytic enzymes were expressed in tissue specimen from two glioblastoma patients, which indicates that a subset of tumor cells is likely able to metabolize ketones. This was discussed as part of the explanation why treatment with a restricted KD failed in retarding these patient’s tumor growth, despite significant reductions in blood glucose and increases in ketone body levels [33].

Changing tumor signaling networks

Several studies emphasized the possibility of a KD to alter signaling networks in tumor cells [28, 34, 35, 86, 88]. One case study described favorable changes in HER2 and

Table 2 Evidence for the hypotheses that a KD has a positive or negative impact on tumor biology, respectively, each time compared to the hypothesis of no or a neutral impact

Study type	N	Evidence for anti-tumor effect			Evidence for pro-tumor effect		
		Yes	No	Unclear/NA	Yes	No	Unclear/NA
<i>Animal studies</i>							
RCT	27	19	5	3	1	26	0
Meta-Analysis	2	2	0	0	0	2	0
<i>Human studies</i>							
Case studies	14	7	3	4	1	13	0
Cohort studies	10	3	4	3	0	8	2

“Unclear” evidence is defined as a likelihood ratio close to 1, i.e., neither evidence for the one or the other hypothesis

Table 3 Evidence for the hypotheses that a KD has a positive or negative impact on quality of life (QoL), respectively, each time compared to the hypothesis of no or a neutral impact

Study type	N	Evidence for positive effect on QoL			Evidence for negative effect on QoL		
		Yes	No	Unclear/NA	Yes	No	Unclear/NA
Case studies	14	7	3	4	0	9	5
Cohort studies	10	5	3	2	1	7	2

“Unclear” evidence is defined analogous to Table 2

progesterone receptor expression during a 3-week KD supplemented with olive oil and high doses of vitamin D in a breast cancer patient, concluding that both oleic acid and the KD might have worked synergistically to downregulate HER2 expression [32].

The insulin/insulin-like growth factor (IGF) axis has repeatedly been implicated as a major modulator of a complex downstream signaling network in tumor cells including the MAPK and the PI3K-Akt-mTOR pathways [98, 99]. Based on this rationale, Fine et al. [86] studied a KD over 4 weeks in ten advanced cancer patients. They found that insulin levels correlated inversely with ketosis, which in turn was correlated with less tumor progression in FDG-PET scans. As the authors themselves stated in their discussion, the outcome “*was not a remarkable finding for a short study considering the variable course of even aggressive cancers*”, so the evidence for the anti-tumor effect hypothesis from this study remains unclear. Cho-Shore and colleagues tested whether KD-mediated mTOR inhibition could slow down growth of tuberous sclerosis complex (TSC) tumors in patients who had started the diet for management of intractable epilepsy [28]. While three of five patients showed improved or complete seizure control, the KD was not able to slow down or inhibit tumor growth; only one patient showed regression of a previously growing subependymal giant cell tumor when he was placed on concomitant treatment with the mTOR inhibitor sirolimus [28]. A subsequent animal model of TSC tumor development showed that while the KD given to Eker rats induced anti-tumor effects in the short term, its long-term

(8 months) administration resulted in elevated growth hormone concentrations, MAPK-ERK1/2 and mTOR hyperactivation and accelerated renal tumor growth [66]. This mechanism is consistent with the conclusion of Chu-Shore et al. that in three children with TSC who were on the diet for more than four years, “*the rate of progression or development of new tumors was more than expected in the natural history of TSC*” [28].

Positive influence on body composition

Free fatty acids and ketone bodies are considered to become a major fuel for normal tissues of cancer patients as a consequence of developing insulin resistance [5]. Additionally, ketone bodies have been shown to suppress protein catabolism during starvation [100]. Based on this rationale, Fearon et al. [26] applied a medium-chain triglyceride-based KD to five severely cachectic cancer patients for 1 week. While nitrogen balance was unaltered compared to the previous normal diet, the KD induced a significant weight gain of 2 kg and improved their performance status.

In a series of ambulatory patients eating a KD during the course of their radiotherapy in our institution, we found that their relative percentage of fat mass decreased but relative percentage of fat free mass increased while patients lost weight [36]. This was taken as evidence that a KD could positively influence body composition and will be investigated further in a currently running clinical trial [101].

Mechanistically, ketone bodies have been shown to exert anti-cachectic effects by curtailing both the cause and the symptoms of cachexia. In a pancreatic cancer model, the first action was related to the inhibition of glycolytic metabolism in tumor cells, while the second effect was mediated by an in situ down-regulation of skeletal muscle and adipose tissue degrading proteins [55]. The relation between cachexia and glycolytic tumor metabolism and tumor size is consistent with the classical study by Fearon and colleagues in the Walker 256 sarcoma of the rat, in which ketosis was not able to significantly reduce blood glucose levels, tumor growth, or weight loss [74]. The significance of the second effect—a direct action of ketone bodies on muscle and adipose tissue—is consistent with the seminal studies of the MAC16 cachectic mouse adenocarcinoma showing that the maintenance of body weight was greater than anticipated solely from the reduction in tumor size [38].

Synergism with radio- and chemotherapy

Besides impaired oxidative energy production, dysfunctional mitochondria in tumor cells are believed to lead to increased steady-state levels of reactive molecules such as superoxide anion (O_2^-) and hydrogen peroxide (H_2O_2). Enhanced glycolysis helps to scavenge high steady-state levels of these reactive oxygen species (ROS) through increased production of anti-oxidative substrates such as lactate, pyruvate, and NADPH [6, 90]. A down-regulation of this anti-oxidative defense mechanism, achieved through glucose withdrawal in vitro [102] or KDs in vivo [51], has been shown to sensitize such tumor cells to additional therapy-induced oxidative stress, while normal cells are left unaffected or even protected [7].

Animal studies provide evidence for the hypothesis that KDs enhance the effects of oxidative stress-inducing therapies such as hyperbaric oxygen [53], radio- and chemotherapy [49, 51]. Based on these data, a confirmation of this hypothesis can be found in the case report of a glioblastoma patient showing complete remission after treatment with a restricted KD, radiotherapy and temozolomide [84] as well as our case study of patients undergoing a KD during curative radiotherapy [36] who remain tumor-free after a median follow-up of 112 weeks (unpublished data). However, these data are not evidentially significant because they are not able to distinguish whether the KD contributed to these outcomes or not.

The phase 1 ketolung and ketopan studies were specifically conducted against this background in order to test the feasibility of a 4:1 KD supplying 90% energy from fat and 8% from protein [71]. The diet was highly artificial, with the usual breakfast made from KetoCal[®] powder and

artificial flavorings, as well as low-carbohydrate versions of milk, bread, and desserts. This KD was poorly tolerated, as only two out of nine patients in the ketolung trial and one of two patients in the ketopan study were able to follow it over the whole course of radiotherapy, and patients experienced several side effects of which at least one, a grade 4 hyperuricemia, was possibly related to the diet. Plasma protein carbonyl content was significantly higher after the KD and radio-chemotherapy intervention, indicating an increase in steady-state levels of ROS-damaged proteins. Again, however, the lack of a control group did not allow any conclusions about the KD contributing to the increased oxidative stress or not.

Discussion

KDs have been studied in a wide variety of contexts reflecting the broad spectrum of current cancer care. Despite the limitations of these studies which mostly consist of case reports, their data are therefore relevant for judging and comparing hypotheses about the effects of KDs for cancer patients in a real-world setting. Earlier reviews have focused on specific mechanisms of the KD [6] or specific contexts in which it is applied [7, 9]. This review differs from these works by focusing more broadly on the benefits of KDs for cancer patients within a clear framework of evidence and confirmation.

We can now try to answer the three questions posed in the introduction. The confirmation question was: Given the available data—now collated in this review—to which degree should we believe that KDs have beneficial effects for cancer patients? The answer depends on the prior probability that we give to this hypothesis and insofar is always subjective. If the animal studies with their various tumor models evaluated here are taken to estimate a prior probability for the hypothesis that KDs exhibit anti-tumor effects in (at least some) cancer patients, this prior probability appears high (72% of the animal studies supported anti-tumor effects). Its posterior probability would be even higher, considering that there are human data of some (exceptional) responses to the KD [14, 27, 89], as well as other data relevant in this context such as the consistent correlations between high blood glucose levels and poor outcome in a variety of human cancers [103–113]. However, a “fundamentalist” skeptic² could always consider such correlations as non-causal (despite mechanistic

² A distinction should be made between “fundamentalist” skepticism, a term coined by M.M. Ćirković [125] and other, more rational forms of skepticism that for example acknowledge the mechanistic data, but consider the human data not supportive for methodological reasons. Examples of the former have been criticized by us previously [117, 126].

reasoning suggesting otherwise [114]) and reject the translatability of animal and in vitro studies to humans. The published cases with positive responses to the KD would hardly shift such a skeptic's position that there are no anti-tumor effects exerted by the KD. Even in this case, however, the prior probability for the hypothesis that KDs accelerates tumor growth would have to be judged low and the posterior even lower given the lack of human data supporting it. Therefore, the hypothesis of an anti-tumor effect of the KD (at least in some patients) is currently confirmed to a much larger degree than the hypothesis of a tumor growth promoting effect. The available data also confirm the hypothesis that KDs are generally safe for cancer patients. In fact, nutritional ketosis is a physiological condition that probably was highly prevalent during human evolution [115, 116], providing little a priori reason to believe that nutritional ketosis *per se* is unsafe or even dangerous. Again, a fundamentalist skeptic would reject the prior assumption of the safety of a diet appearing extreme compared to dietary guidelines and could point to putative side effects that have been mostly observed in the pediatric population treated with very strict and partially outdated forms of KDs [117].

But is there actual evidence for serious side effects in cancer patients? Serious side effects (grade ≥ 2) reported in the literature are scarce and correlate with extreme versions of the diet, with either concurrent caloric restriction (weight loss [84], fatigue [31]), or extreme macronutrient compositions (hyperuricemia [71]). The ketolung and ketopan studies [71] were important in showing that an artificial 90% fat, 8% protein diet is hardly sustainable. Such low-protein content is at odds with protein requirements of cancer patients which are estimated as at least 1.2 g/kg body weight/day with ideal intakes of at least 2 g/kg/day for patients in advanced stages [118]. Sufficient intake of high-quality protein is important for preserving skeletal muscle mass, the loss of which is much more problematic than that of fat mass [90]. Along these lines, while most of the studies reported weight loss to some extent, this should always be interpreted within the specific study context [117], and for certain patient groups could even be seen as beneficial in terms of QoL and long-term outcome [119]. An important finding was that across all settings, half of the studies even provided evidence for an improvement in QoL, an outcome that was rarely mentioned as a primary study goal. Thus, future studies could specifically be designed to investigate which aspects of QoL are influenced by a KD and what constitutes the mechanisms.

Is there evidence for anti-tumor effects in patients? Evidence for the anti-tumor hypothesis is currently limited and of low strength in the human data (Table 2). This is partly based on the design of the studies undertaken so far

that does not allow discriminating between the anti-tumor hypothesis and the hypothesis of a neutral or no effect. From a realist standpoint, the biochemical events that determine the effects of a KD on tumor cells under different contexts or boundary conditions are *ontological aspects* that are essential for explaining and predicting individual patient outcomes [20]. Unfortunately, the causation question concerning a mechanistic explanation of observed study outcomes has been left unanswered in most cases. While most researchers agree on the causal importance of lowering blood glucose levels and increasing ketone body levels for achieving a therapeutic effect, there are still too many unknowns in the inferential chain linking these metabolic changes to patient-relevant outcomes, and currently running controlled trials will be of great value for filling these knowledge gaps [9].

Finally, given the above answers to the confirmation and evidence questions, which advice can be given to cancer patients and their physicians (the *decision* question)? It is clear that with many cancer patients wishing to try a ketogenic diet and seeking professional guidance to do so safely, we cannot wait until results of RCTs have been obtained (if they ever will) [120]. Patients should be informed about the totality of evidence including plausible mechanistic reasoning and the current limitations of evidence from human data, a situation typical for an emerging new treatment. The data implicate that a logical argument can be derived stating that KDs could safely be offered to patients, since the probability of potential benefits appears much larger than the probability of serious side effects. Of course, this includes the assumption of a setting in which patients are both intrinsically motivated and externally supervised, and the diet fulfills the protein and micronutrient requirements. Again, this judgement is largely subjective and more objective evidence needs to be gathered from further mechanistic studies, larger case series and—most importantly—controlled clinical trials.

A limitation of this review is that one could question the assignment of evidence for the anti-tumor effect hypothesis to particular study data as given in Table 1. I tried to objectively evaluate alternative hypotheses appearing realistic within the context of each particular study, but did not consider any form of *ad hoc* hypothesis such as a spontaneous remission as likely. The comments on effect details in Table 1 have been included to justify my assignment of evidence. The definition of evidence that I used could also be criticized. For example, Cartwright et al. find “*probabilistic relations between the evidence and the hypothesis...not useful for evidence-based policy*” [121], while at the same admitting that we have no practicable theory of evidence. Again, their statement exemplifies the confusion between evidence and data. The distinction between evidence, confirmation and data used herein has

been shown to overcome a variety of scientific and philosophical paradoxes [15] and distinguishes this work from others that refer to evidence without having a clear concept of this term. The evidential conclusions drawn from the studies are robust against other measures of evidence as long as they incorporate the comparison between two hypotheses.

As a cautionary note, some recent animal experiments have revealed tumor growth stimulation through administration of ketone bodies [68, 122, 123]. Two studies using breast cancer models showed that BHB infusions accelerated tumor growth by serving as an energetic substrate for oxidative (non-Warburg) tumor cells [122, 123]. Since no KD was applied, no evidence for or against its use can be derived from these data. The study of Xia et al. [68] showed that acetoacetate, but not BHB, accelerated tumor growth of BRAF V600E-expressing melanoma xenografts, which led the authors to express concerns about KDs for patients with tumors that harbor such mutations. However, in this study, a KD did only increase acetoacetate, but not BHB levels, which makes this KD appear different from all other animal experiments and questionable as a model system for a KD applied to humans where ketosis is characterized by more than fourfold lower acetoacetate than BHB levels [124]. It is also noteworthy that the best response to a KD in the study by Tan-Shalaby et al. [14] was seen in a patient with BRAF-V600 positive stage IV melanoma who stayed tumor-free after surgery and a prolonged KD at 131 weeks of follow-up. Based on these animal data, the possibility that a subset of human tumors could be stimulated by a KD should therefore be considered, but is not justified by the human data published so far and not even supported by evidence from these studies themselves (because a KD was not used in two of them and elicited completely different effects to a KD in humans in the third).

Conclusions

KDs have been studied in humans in a wide variety of contexts that are representative of modern cancer treatment. Due to a lack of controlled trials, the human data are only able to provide very low level evidence for anti-tumor effects of KDs which is also limited to individual cases. The total evidence is upgraded to some extent by mechanistic reasoning. Nevertheless, some exceptional responses have justified the belief that KDs can exert anti-tumor effects at least for some patients because the posterior probability for this hypothesis is higher than for its alternatives. Furthermore, there is no evidence or reason to believe that KDs have serious side effects or would accelerate tumor growth. The logical conclusion is

therefore that KDs are promising and worth of further study since the probability of achieving an anti-tumor effect is apparently greater than that of causing serious side effects.

Compliance with ethical standards

Conflict of interest The author declares that he has no conflict of interest.

Ethical approval This review was undertaken without requesting ethical approval, since ethical approval was granted for most of the included studies, all human data were anonymous, and the ethical recommendations of the Declaration of Helsinki were adhered to.

References

1. Paoli A, Rubini A, Volek JS, Grimaldi KA. Beyond weight loss: a review of the therapeutic uses of very-low-carbohydrate (ketogenic) diets. *Eur J Clin Nutr.* 2013;67:789–96.
2. Seyfried TN, Flores RE, Poff AM, D'Agostino DP. Cancer as a metabolic disease: implications for novel therapeutics. *Carcinogenesis.* 2014;35:515–27.
3. Vidali S, Aminzadeh S, Lambert B, Rutherford T, Sperl W, Kofler B, et al. Mitochondria: the ketogenic diet—a metabolism-based therapy. *Int J Biochem Cell Biol.* 2015;63:55–9.
4. Seyfried TN, Yu G, Maroon JC, D'Agostino DP. Press-pulse: a novel therapeutic strategy for the metabolic management of cancer. *Nutr Metab (Lond).* 2017;14:19.
5. Klement RJ, Kämmerer U. Is there a role for carbohydrate restriction in the treatment and prevention of cancer? *Nutr Metab (Lond).* 2011;8:75.
6. Allen BG, Bhatia SK, Anderson CM, Eichenberger-Gilmore JM, Sibenaller ZA, Mapuskar KA, et al. Ketogenic diets as an adjuvant cancer therapy: history and potential mechanism. *Redox Biol.* 2014;2C:963–70.
7. Klement RJ, Champ CE. Calories, carbohydrates, and cancer therapy with radiation: exploiting the five R's through dietary manipulation. *Cancer Metasta Rev.* 2014;33:217–29.
8. Woolf EC, Syed N, Scheck AC. Tumor metabolism, the ketogenic diet and β -hydroxybutyrate: novel approaches to adjuvant brain tumor therapy. *Front Mol Neurosci.* 2016;9:122.
9. Winter SF, Loebel F, Dietrich J. Role of ketogenic metabolic therapy in malignant glioma: a systematic review. *Crit Rev Oncol Hematol.* 2017;112:41–58.
10. Huebner J, Marienfeld S, Abbenhardt C, Ulrich C, Muenstedt K, Micke O, et al. Counseling patients on cancer diets: a review of the literature and recommendations for clinical practice. *Anit-cancer Res.* 2014;34:39–48.
11. Howick J. *The philosophy of evidence-based medicine.* 1st ed. Oxford: Wiley; 2011.
12. Walach H, Falkenberg T, Fønnebo V, Lewith G, Jonas WB. Circular instead of hierarchical: methodological principles for the evaluation of complex interventions. *BMC Med Res Methodol.* 2006;6:29.
13. Walach H, Loef M. Using a matrix-analytical approach to synthesizing evidence solved incompatibility problem in the hierarchy of evidence. *J Clin Epidemiol.* 2015;68:1251–60.
14. Tan-Shalaby JL, Carrick J, Edinger K, Genovese D, Liman AD, Passero VA, et al. Modified Atkins diet in advanced malignancies: final results of a safety and feasibility trial within the

- Veterans Affairs Pittsburgh Healthcare System. *Nutr Metab (Lond)*. 2016;13:52.
15. Bandyopadhyay PS, Brittan G Jr, Taper ML. *Belief, evidence, and uncertainty: problems of Epistemic inference*. 1st ed. Berlin: Springer Nature; 2016.
 16. Carnap R. On the application of inductive logic. *Philos Phenomenol Res*. 1947;8:133–48.
 17. Pawson R, Greenhalgh T, Harvey G, Walshe K. Realist review—a new method of systematic review designed for complex policy interventions. *J Health Serv Res Policy*. 2005;10:21–34.
 18. Greenhalgh T, Wong G, Westhorp G, Pawson R. Protocol—realist and meta-narrative evidence synthesis: evolving standards (RAMESES). *BMC Med Res Methodol*. 2011;11:115.
 19. Wong G, Greenhalgh T, Westhorp G, Buckingham J, Pawson R, Pawson R, et al. RAMESES publication standards: realist syntheses. *BMC Med*. 2013;11:21.
 20. Aronson JL. *A realist philosophy of science*. 1st ed. London: The Macmillan Press Ltd; 1984.
 21. Pérez-Guisado J, Muñoz-Serrano A, Alonso-Moraga Á. Spanish Ketogenic Mediterranean diet: a healthy cardiovascular diet for weight loss. *Nutr J*. 2008;7:30.
 22. Clemens Z, Kelemen A, Fogarasi A, Tóth C. Childhood absence epilepsy successfully treated with the Paleolithic Ketogenic diet. *Neurol Ther*. 2013;2:71–6.
 23. Nebeling LC, Lerner E. Implementing a ketogenic diet based on medium-chain triglyceride oil in pediatric patients with cancer. *J Am Diet Assoc*. 1995;95:693–7.
 24. Jenkins DJA, Wong JMW, Kendall CWC, Esfahani A, Ng VWY, Leong TCK, et al. The effect of a plant-based low-carbohydrate (“Eco-Atkins”) diet on body weight and blood lipid concentrations in hyperlipidemic subjects. *Arch Intern Med*. 2009;169:1046–54.
 25. Walach H. Mehr Daten? Mehr denken? Umdenken! *Forschende Komplementärmedizin/Res Complement Med*. 2016;23:3–5.
 26. Fearon KC, Borland W, Preston T, Tisdale MJ, Shenkin A, Calman KC. Cancer cachexia: influence of systemic ketosis on substrate levels and nitrogen metabolism. *Am J Clin Nutr*. 1988;47:42–8.
 27. Nebeling L, Miraldi F, Shurin S, Lerner E. Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients: two case reports. *J Am Coll Nutr*. 1995;14:202–8.
 28. Chu-Shore CJ, Thiele EA. Tumor growth in patients with tuberous sclerosis complex on the ketogenic diet. *Brain Dev*. 2010;32:318–22.
 29. Schmidt M, Pfetzer N, Schwab M, Strauss I, Kämmerer U. Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: a pilot trial. *Nutr Metab (Lond)*. 2011;8:54.
 30. Schroeder U, Himpe B, Pries R, Vonthein R, Nitsch S, Woltenberg B. Decline of lactate in tumor tissue after ketogenic diet: in vivo microdialysis study in patients with head and neck cancer. *Nutr Cancer*. 2013;65:843–9.
 31. Champ CE, Palmer JD, Volek JS, Werner-Wasik M, Andrews DW, Evans JJ, et al. Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme. *J Neurooncol*. 2014;117:125–31.
 32. Branca JJV, Pacini S, Ruggiero M. Effects of Pre-surgical vitamin D supplementation and Ketogenic Diet in a patient with recurrent breast cancer. *Anticancer Res*. 2015;35:5525–32.
 33. Schwartz K, Chang HT, Nikolai M, Pernicone J, Rhee S, Olson K, et al. Treatment of glioma patients with ketogenic diets: report of two cases treated with an IRB-approved energy-restricted ketogenic diet protocol and review of the literature. *Cancer Metab*. 2015;3:3.
 34. Strowd RE, Cervenka MC, Henry BJ, Kossoff EH, Hartman AL, Blakeley JO. Glycemic modulation in neuro-oncology: experience and future directions using a modified Atkins diet for high-grade brain tumors. *Neurooncol Pract*. 2015;2:127–36.
 35. Jansen N, Walach H. The development of tumours under a ketogenic diet in association with the novel tumour marker TKTL1: a case series in general practice. *Oncol Lett*. 2016;11:584–92.
 36. Klement RJ, Sweeney RA. Impact of a ketogenic diet intervention during radiotherapy on body composition: I. Initial clinical experience with six prospectively studied patients. *BMC Res Notes*. 2016;9:143.
 37. Artzi M, Liberman G, Vaisman N, Bokstein F, Vitinshtein F, Aizenstein O, et al. Changes in cerebral metabolism during ketogenic diet in patients with primary brain tumors: 1H-MRS study. *J Neurooncol*. 2017;132:267–75.
 38. Tisdale MJ, Brennan RA, Fearon KC. Reduction of weight loss and tumour size in a cachexia model by a high fat diet. *Br J Cancer*. 1987;56:39–43.
 39. Tisdale MJ, Brennan RA. A comparison of long-chain triglycerides and medium-chain triglycerides on weight loss and tumour size in a cachexia model. *Br J Cancer*. 1988;58:580–3.
 40. Beck SA, Tisdale MJ. Effect of insulin on weight loss and tumour growth in a cachexia model. *Br J Cancer*. 1989;59:677–81.
 41. Seyfried TN, Sanderson TM, El-Abbadi MM, McGowan R, Mukherjee P. Role of glucose and ketone bodies in the metabolic control of experimental brain cancer. *Br J Cancer*. 2003;89:1375–82.
 42. Zhou W, Mukherjee P, Kiebish MA, Markis WT, Mantis JG, Seyfried TN. The calorically restricted ketogenic diet, an effective alternative therapy for malignant brain cancer. *Nutr Metab (Lond)*. 2007;4:5.
 43. Freedland SJ, Mavropoulos J, Wang A, Darshan M, Demark-Wahnefried W, Aronson WJ, et al. Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis. *Prostate*. 2008;68:11–9.
 44. Otto C, Kaemmerer U, Illert B, Muehling B, Pfetzer N, Wittig R, et al. Growth of human gastric cancer cells in nude mice is delayed by a ketogenic diet supplemented with omega-3 fatty acids and medium-chain triglycerides. *BMC Cancer*. 2008;8:122.
 45. Mavropoulos JC, Buschemeyer WC 3rd, Tewari AK, Rokhfeld D, Pollak M, Zhao Y, et al. The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft model. *Cancer Prev Res*. 2009;2:557–65.
 46. Masko EM, Thomas JA 2nd, Antonelli JA, Lloyd JC, Phillips TE, Poulton SH, et al. Low-carbohydrate diets and prostate cancer: how Low Is “Low Enough”? *Cancer Prev Res*. 2010;3:1124–31.
 47. Stafford P, Abdelwahab MG, Kim DY, Preul MC, Rho JM, Scheck AC. The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma. *Nutr Metab (Lond)*. 2010;7:74.
 48. Maurer GD, Brucker DP, Bähr O, Harter PN, Hattingen E, Walenta S, et al. Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy. *BMC Cancer*. 2011;11:315.
 49. Abdelwahab MG, Fenton KE, Preul MC, Rho JM, Lynch A, Stafford P, et al. The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma. *PLoS ONE*. 2012;7:e36197.
 50. Kim HS, Masko EM, Poulton SL, Kennedy KM, Pizzo SV, Dewhirst MW, et al. Carbohydrate restriction and lactate

- transporter inhibition in a mouse xenograft model of human prostate cancer. *BJU Int.* 2012;110:1062–9.
51. Allen BG, Bhatia SK, Buatti JM, Cancer C, Published R, June O. Ketogenic diets enhance oxidative stress and radio-chemotherapy responses in lung cancer Xenografts Ketogenic diets enhance oxidative stress and radio-chemotherapy responses in lung cancer xenografts. *Clin Cancer Res.* 2013;19:3905–13.
 52. Caso J, Masko EM, Thomas JA II, Poulton SH, Dewhirst M, Pizzo SV, et al. The effect of carbohydrate restriction on prostate cancer tumor growth in a castrate mouse xenograft model. *Prostate.* 2013;73:449–54.
 53. Poff AM, Ari C, Seyfried TN, Agostino DP. The Ketogenic diet and hyperbaric oxygen therapy prolong survival in mice with systemic metastatic cancer. *PLoS ONE.* 2013;8:e65522.
 54. Husain Z, Huang Y, Seth P, Sukhatme VP. Tumor-derived lactate modifies antitumor immune response: effect on Myeloid-Derived suppressor cells and NK cells. *J Immunol.* 2014;191:1486–95.
 55. Shukla SK, Gebregiorgis T, Purohit V, Chaika NV, Gunda V, Radhakrishnan P, et al. Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia. *Cancer Metab.* 2014;2:18.
 56. Zhuang Y, Chan DK, Haugrud AB, Miskimins WK. Mechanisms by which low glucose enhances the cytotoxicity of metformin to cancer cells both in vitro and in vivo. *PLoS ONE.* 2014;9:e108444.
 57. Gluschnaider U, Hertz R, Ohayon S, Smeir E, Smets M, Pikarsky E, et al. Long-chain fatty acid analogues suppress breast tumorigenesis and progression. *Cancer Res.* 2014;74:6991–7002.
 58. Healy ME, Chow JDY, Byrne FL, Breen DS, Leitinger N, Li C, et al. Dietary effects on liver tumor burden in mice treated with the hepatocellular carcinogen diethylnitrosamine. *J Hepatol.* 2015;62:599–606.
 59. Hao G-W, Chen Y-S, He D-M, Wang H-Y, Wu G-H, Zhang B. Growth of human colon cancer cells in nude mice is delayed by Ketogenic diet with or without Omega-3 fatty acids and medium-chain triglycerides. *Asian Pac J Cancer Prev.* 2015;16:2061–8.
 60. Morscher RJ, Aminzadeh-Gohari S, Feichtinger RG, Mayr JA, Lang R, Neureiter D, et al. Inhibition of neuroblastoma tumor growth by Ketogenic Diet and/or calorie restriction in a CD1-Nu mouse model. *PLoS ONE.* 2015;10:e0129802.
 61. Poff AM, Ward N, Seyfried TN, Arnold P, D'Agostino DP. Non-toxic metabolic management of metastatic cancer in VM mice: novel combination of Ketogenic Diet, Ketone supplementation, and hyperbaric oxygen therapy. *PLoS ONE.* 2015;10:e0127407.
 62. Woolf EC, Curley KL, Liu Q, Turner GH, Charlton JA, Preul MC, et al. The Ketogenic Diet alters the hypoxic response and affects expression of proteins associated with angiogenesis, invasive potential and vascular permeability in a mouse glioma model. *PLoS One.* 2015;10:e0130357.
 63. Stemmer K, Zani F, Habegger KM, Neff C, Kotzbeck P, Bauer M, et al. FGF21 is not required for glucose homeostasis, ketosis or tumour suppression associated with ketogenic diets in Mice. *Diabetologia.* 2015;58:2414–23.
 64. Dang MT, Wehrli S, Dang CV, Curran T. The Ketogenic Diet does not affect growth of Hedgehog pathway Medulloblastoma in Mice. *PLoS ONE.* 2015;10:e0133633.
 65. Martuscello RT, Vedam-Mai V, McCarthy DJ, Schmoll ME, Jundi MA, Louviere CD, et al. A supplemented high-fat low-carbohydrate diet for the treatment of glioblastoma. *Clin Cancer Res.* 2016;22:2482–95.
 66. Liśkiewicz AD, Kasprowska D, Wojakowska A, Polański K, Lewin-Kowalik J, Kotulska K, et al. Long-term high fat Ketogenic Diet promotes renal tumor growth in a rat model of Tuberosus Sclerosis. *Sci Rep.* 2016;6:21807.
 67. Lussier DM, Woolf EC, Johnson JL, Brooks KS, Blattman JN, Scheck AC. Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic Ketogenic diet. *BMC Cancer.* 2016;16:10.
 68. Xia S, Lin R, Jin L, Zhao L, Kang H-B, Pan Y, et al. Prevention of dietary-fat-fueled Ketogenesis attenuates BRAF V600E tumor growth. *Cell Metab.* 2017;25:358–73.
 69. Allott EH, Macias E, Sanders S, Knudsen BS, Thomas G V, Hursting SD, et al. Impact of carbohydrate restriction in the context of obesity on prostate tumor growth in the Hi-Myc transgenic mouse model. *Prostate Cancer Prostatic Dis.* 2017;20:165–71.
 70. Rieger J, Bähr O, Maurer GD, Hattingen E, Franz K, Brucker D, et al. ERGO: a pilot study of ketogenic diet in recurrent glioblastoma. *Int J Oncol.* 2014;44:1843–52.
 71. Zahra A, Fath MA, Opat E, Mapuskar KA, Bhatia SK, Ma DC, et al. Consuming a Ketogenic Diet while receiving radiation and chemotherapy for locally advanced lung cancer and pancreatic cancer: The University of Iowa experience of two phase I clinical trials. *Radiat Res.* 2017;187:743–54.
 72. Lv M, Zhu X, Wang H, Wang F, Guan W. Roles of caloric restriction, ketogenic diet and intermittent fasting during initiation, progression and metastasis of cancer in animal models: a systematic review and meta-analysis. *PLoS ONE.* 2014;9:e115147.
 73. Klement RJ, Champ CE, Otto C, Kämmerer U. Anti-tumor effects of Ketogenic diets in Mice: a meta-analysis. *PLoS ONE.* 2016;11:e0155050.
 74. Fearon KC, Tisdale MJ, Preston T, Plumb JA, Calman KC. Failure of systemic ketosis to control cachexia and the growth rate of the Walker 256 carcinosarcoma in rats. *Brit J Cancer.* 1985;52:87–92.
 75. Beck SA, Tisdale MJ. Nitrogen excretion in cancer cachexia and its modification by a high fat diet in Mice. *Cancer Res.* 1989;49:3800–4.
 76. Otto C, Klingelhöffer C, Biggermann L, Melkus G, Mörchel P, Jürgens C, et al. Analysis of the metabolism of Ketone Bodies and lactate by gastrointestinal tumor cells in vitro. *Aktuel Ernährungsmed.* 2014;39:51–9.
 77. Hao G, Wang H, He D, Chen Y, Wu G, Zhang B. Effect of ketogenic diet on growth of human colon cancer cells in nude mice. *Chinese J Clin Oncol.* 2014;41:1154–7.
 78. Liu R-Q, Liu M-F, Jiang X-C, Guo Z-Z, Dong J-Y, Chen R, et al. Ketogenic diet affects tumor growth in the mouse model of EMT-6 breast cancer. *Chinese J Cancer Prev Treat.* 2015;22:827–31.
 79. De Feyter HM, Behar KL, Rao JU, Madden-Hennessey K, Ip KL, Hyder F, et al. A ketogenic diet increases transport and oxidation of ketone bodies in RG2 and 9L gliomas without affecting tumor growth. *Neuro Oncol.* 2016;18:1079–87.
 80. Healy ME, Lahiri S, Hargett SR, Chow JDY, Byrne FL, Breen DS, et al. Dietary sugar intake increases liver tumor incidence in female mice. *Sci Rep.* 2016;6:22292.
 81. Brünings W. Beiträge zum Krebsproblem. 1. Mitteilung: Ueber eine diätetisch-hormonale Beeinflussung des Krebses. *Münch Med Wschr.* 1941;88:117–23.
 82. Brünings W. Beiträge zum Krebsproblem. 2. Mitteilung: Klinische Anwendungen der diätetisch-hormonalen Krebsbeeinflussung ("Entzuckerungsmethode"). *Münch Med Wschr.* 1942; 89: 71–6.
 83. Schulte G, Schütz H. Insulin in der Krebsbehandlung. *Münch Med Wschr.* 1942;89:648–50.
 84. Zuccoli G, Marcello N, Pisanello A, Servadei F, Vaccaro S, Mukherjee P, et al. Metabolic management of glioblastoma

- multiforme using standard therapy together with a restricted ketogenic diet: case report. *Nutr Metab.* 2010;7:33.
85. Moore K. Using the restricted ketogenic diet for brain cancer management: comments from neuro-oncologist. In: Seyfried TN, editor. *Cancer as a metabolic disease: on the origin, management, and prevention of cancer.* Hoboken: Wiley; 2012. p. 397–400.
 86. Fine EJ, Segal-isaacson CJ, Feinman RD, Herszkopf S, Romano MC, Tomuta N, et al. Targeting insulin inhibition as a metabolic therapy in advanced cancer: a pilot safety and feasibility dietary trial in 10 patients. *Nutrition.* 2012;28:1028–35.
 87. Tóth C, Clemens Z. Halted progression of soft palate cancer in a patient treated with the paleolithic Ketogenic Diet alone. *Am J Med Case Reports.* 2016;4:288–92.
 88. Schwalb M, Taubmann M, Hines S, Reinwald H, Ruggiero M. Clinical observation of a novel, complementary, immunotherapeutic approach based on Ketogenic diet, chondroitin sulfate, vitamin D 3, oleic acid and a fermented milk and colostrum product. *Am J Immunol.* 2016;12:91–8.
 89. Abdelbary M, Elsakka A, Salah H, Mokhtar W, Abdelzaher E. Does Metabolic management of gliomas using restricted Ketogenic diet combined with hyperbaric oxygen therapy (HBOT) improve clinical outcome and reduce epileptic risk? (poster presentation). Tampa: Metabolic Therapeutics Conference; 2017.
 90. Klement RJ. Restricting carbohydrates to fight head and neck cancer—is this realistic? *Cancer Biol Med.* 2014;11:145–61.
 91. Warburg O, Posener K, Negelein E. Über den Stoffwechsel der Carcinomzelle. *Biochem Zeitschr.* 1924;152:309–43.
 92. Fine EJ, Miller A, Quadros EV, Sequeira JM, Feinman RD. Acetoacetate reduces growth and ATP concentration in cancer cell lines which over-express uncoupling protein 2. *Cancer Cell Int.* 2009;9:14.
 93. Seyfried TN, Shelton LM. Cancer as a metabolic disease. *Nutr Metab (Lond).* 2010;7:7.
 94. Seyfried TN. *Cancer as a metabolic disease: on the origin, management, and prevention of cancer.* Hoboken: Wiley; 2012.
 95. Marchut E, Gumińska M, Kedryna T. The inhibitory effect of various fatty acids on aerobic glycolysis in Ehrlich ascites tumour cells. *Acta Biochim Pol.* 1985;33:7–16.
 96. Nakahara W. Studies on Lymphoid activity. VI. Immunity to transplanted cancer induced by injection of olive oil. *J Exp Med.* 1921;35:493–505.
 97. Nakahara W. Effect of fatty acids on the resistance of mice to transplanted cancer. *J Exp Med.* 1924;40:363–73.
 98. Fine EJ, Feinman RD. Insulin, carbohydrate restriction, metabolic syndrome and cancer. *Exp Rev Endocrin Metab.* 2014;10:15–24.
 99. Klement RJ, Fink MK. Dietary and pharmacological modification of the insulin/IGF-1 system: exploiting the full repertoire against cancer. *Oncogenesis.* 2016;5:e193.
 100. Sherwin RS, Hendler R, Felig P. Effect of ketone infusions on amino acid and nitrogen metabolism in man. *J Clin Invest.* 1975;55:1382–90.
 101. Klement RJ, Sweeney RA. Impact of a ketogenic diet intervention during radiotherapy on body composition: II. Protocol of a randomised phase I study (KETOCOMP). *Clin Nutr ESPEN.* 2016;12:e1–6.
 102. Ahmad IM, Aykin-Burns N, Sim JE, Walsh SA, Higashikubo R, Buettner GR, et al. Mitochondrial O₂- and H₂O₂ Mediate glucose deprivation-induced stress in human cancer cells. *J Biol Chem.* 2005;280:4254–63.
 103. Weiser MA, Cabanillas ME, Konopleva M, Thomas DA, Pierce SA, Escalante CP, et al. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. *Cancer.* 2004;100:1179–85.
 104. McGirt MJ, Chaichana KL, Gathinji M, Attenello F, Than K, Ruiz AJ, et al. Persistent outpatient hyperglycemia is independently associated with decreased survival after primary resection of malignant brain astrocytomas. *Neurosurgery.* 2008;63:286–91.
 105. Derr RL, Ye X, Islas MU, Desideri S, Saudek CD, Grossman SA. Association between hyperglycemia and survival in patients with newly diagnosed glioblastoma. *J Clin Oncol.* 2009;27:1082–6.
 106. Lamkin DM, Spitz DR, Shahzad MMK, Zimmerman B, Lenihan DL, DeGeest K, et al. Glucose as a prognostic factor in Ovarian Carcinoma. *Cancer.* 2009;115:1021–7.
 107. Erickson K, Patterson RE, Flatt SW, Natarajan L, Parker BA, Heath DD, et al. Clinically defined type 2 diabetes mellitus and prognosis in early-stage breast cancer. *J Clin Oncol.* 2011;29:54–60.
 108. Villarreal-Garza C, Shaw-Dulin R, Lara-Medina F, Bacon L, Rivera D, Urzua L, et al. Impact of diabetes and Hyperglycemia on survival in advanced breast cancer patients. *Exp Diabetes Res.* 2012;2012:732027.
 109. Minicozzi P, Berrino F, Sebastiani F, Falcini F, Vattiato R, Cioccoloni F, et al. High fasting blood glucose and obesity significantly and independently increase risk of breast cancer death in hormone receptor-positive disease. *Eur J Cancer.* 2013;49:3881–8.
 110. Mayer A, Vaupel P, Struss H-G, Giese A, Stockinger M, Schmidberger H. Strong adverse prognostic impact of hyperglycemic episodes during adjuvant chemoradiotherapy of glioblastoma multiforme. *Strahlenther Onkol.* 2014;190:933–8.
 111. Tieu MT, Lovblom LE, McNamara MG, Mason W, Laperriere N, Millar B-A, et al. Impact of glycemia on survival of glioblastoma patients treated with radiation and temozolomide. *J Neurooncol.* 2015;124:119–26.
 112. Monzavi-Karbassi B, Gentry R, Kaur V, Siegel ER, Jousheghany F, Medarametla S, et al. Pre-diagnosis blood glucose and prognosis in women with breast cancer. *Cancer Metab.* 2016;4:7.
 113. Adeberg S, Bernhardt D, Foerster R, Bostel T, Koerber SA, Mohr A, et al. The influence of hyperglycemia during radiotherapy on survival in patients with primary glioblastoma. *Acta Oncol (Madr).* 2016;55:201–7.
 114. Klement RJ, Champ CE. Corticosteroids compromise survival in glioblastoma in part through their elevation of blood glucose levels. *Brain.* 2017;140:e16.
 115. Fine EJ, Champ CE, Feinman RD, Márquez S, Klement RJ. An evolutionary and mechanistic perspective on dietary carbohydrate restriction in Cancer Prevention. *J Evo Health.* 2016;1:15.
 116. Clemens Z, Tóth C. Vitamin C and disease: insights from the evolutionary perspective. *J Evo Health.* 2016;1:13.
 117. Klement RJ, Feinman RD, Gross EC, Champ CE, D'Agostino DP, Fine EJ, et al. Need for new review of article on ketogenic dietary regimes for cancer patients. *Med Oncol.* 2017;34:108.
 118. Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, et al. ESPEN guidelines on nutrition in cancer patients. *Clin Nutr.* 2017;36:11–48.
 119. Champ CE, Volek JS, Siglin J, Jin L, Simone NL. Weight Gain, metabolic syndrome, and breast cancer recurrence: are dietary recommendations supported by the data? *Int J Breast Cancer.* 2012;2012:506868.
 120. Gonder U. Article on ketogenic dietary regimes for cancer highly misleading. *Med Oncol.* 2017;34:109.
 121. Cartwright N, Howick J. Evidence-based policy: where is our theory of evidence? *J Child Serv.* 2009;4:6–15.

122. Bonuccelli G, Tsigirgos A, Whitaker-Menezes D, Pavlides S, Pestell RG, Chiavarina B, et al. Ketones and lactate “fuel” tumor growth and metastasis: evidence that epithelial cancer cells use oxidative mitochondrial metabolism. *Cell Cycle*. 2010;9:3506–14.
123. Rodrigues LM, Uribe-Lewis S, Madhu B, Honess DJ, Stubbs M, Griffiths JR. The action of β -hydroxybutyrate on the growth, metabolism and global histone H3 acetylation of spontaneous mouse mammary tumours: evidence of a β -hydroxybutyrate paradox. *Cancer Metab*. 2017;5:4.
124. Cahill GFJ, Veech RL. Ketoacids? Good medicine? *Trans Am Clin Climatol Assoc*. 2003;114:149–61.
125. Ćirković MM. Who are the SETI sceptics? *Acta Astronaut*. 2013;89:38–45.
126. Champ CE, Klement RJ. Commentary on “Strong adverse prognostic impact of hyperglycemic episodes during adjuvant chemoradiotherapy of glioblastoma multiforme”. *Strahlenther Onkol*. 2014;191:281–2.